Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962412 | 1.00 | ADRB1 (0.46) | ADRB1HCRTR1HCRTR2FFAR4NR1H2 | |
| SCHEMBL1964545 | 1.00 | ADRB1 (0.46) | ADRB1HCRTR1HCRTR2FFAR4NR1H2 | |
| SCHEMBL7954354 | 0.91 | ADRB1 (0.49) | ADRB1HCRTR1HCRTR2FFAR4NR1H2 | |
| SCHEMBL11993831 | 0.91 | ADRB1 (0.49) | ADRB1HCRTR1HCRTR2FFAR4NR1H2 | |
| SCHEMBL1964868 | 0.86 | ADRB1 (0.45) | ADRB1HCRTR1HCRTR2FFAR4NR1H2 | |
| SCHEMBL1965218 | 0.86 | ADRB1 (0.45) | ADRB1HCRTR1HCRTR2FFAR4NR1H2 | |
| SCHEMBL12554159 | 0.86 | ADRB1 (0.45) | ADRB1HCRTR1HCRTR2FFAR4NR1H2 | |
| SCHEMBL12554164 | 0.86 | ADRB1 (0.45) | ADRB1HCRTR1HCRTR2FFAR4NR1H2 | |
| SCHEMBL15137215 | 0.74 | FFAR4 (0.44) | ADRB1HCRTR1HCRTR2FFAR4NR1H2 | |
| SCHEMBL1672164 | 0.73 | ADRB1 (0.51) | ADRB1HCRTR1HCRTR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946413-B2 | 3-aminocyclopentanecarboxamides as chemokine receptor agonists | PFIZER INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130197008-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS CHEMOKINE RECEPTOR AGONISTS | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8293903-B2 | 3-aminocyclopentanecarboxamides as chemokine receptor agonists | PFIZER INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293903-B2 | 3-aminocyclopentanecarboxamides as chemokine receptor agonists | PFIZER INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110144129-A1 | 3-Aminocyclopentanecarboxamides as Chemokine Receptor Agonists | PFIZER INC | 2011-06-16 | — | — | US | disclosed |
| US-20110144129-A1 | 3-Aminocyclopentanecarboxamides as Chemokine Receptor Agonists | PFIZER INC | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197008-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS CHEMOKINE RECEPTOR AGONISTS | ACKR3, CCR2, CCR5 | ADRB1 114/4885HCRTR1 140/4885HCRTR2 153/4885 |
| US-20110144129-A1 | 3-Aminocyclopentanecarboxamides as Chemokine Receptor Agonists | ACKR3, CCR2, CCR5 | ADRB1 106/4885HCRTR1 151/4885HCRTR2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.